RxDoctor Payments Data

Cameron Wagenbrenner, MD

Internal Medicine · Colbert, GANPI 1063995561

Payments from drug & device makers

$1,926in general payments, 2019–2025

Across 98 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$283
  • Gilead$234
  • Exact Sciences$194
  • Corcept Therapeutics$186
  • Otsuka America Pharmaceutical, Inc.$120
  • AstraZeneca$117
  • plus $792 from 21 others

What the payments were for

  • Food & beverage$1,926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,926 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$660
Medicare patients
26
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$37,104
FarxigaDapagliflozin Propanediol34$29,725
MounjaroTirzepatide28$29,513
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,823
TrulicityDulaglutide17$15,619
OzempicSemaglutide14$14,767
JardianceEmpagliflozin14$14,154
MyrbetriqMirabegron15$6,818
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl76$5,787
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,208
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$2,752
Albuterol Sulfate HfaAlbuterol Sulfate107$2,487
Humalog Kwikpen U-100Insulin Lispro11$1,793
Gabapentin111$1,747
Aripiprazole27$1,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$58$45,13245 claims
PfizerEliquis$45$37,10435 claims
AstraZenecaFarxiga$117$29,72534 claims
GSKTrelegy Ellipta$91$22,82321 claims
Novo NordiskOzempic$39$14,76714 claims
Boehringer IngelheimJardiance$17$14,15414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Colbert

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →